| Description |
High fructose intake is one of the high-risk factors for hypertension. Several probiotics have been reported to reduce high blood pressure via modulating gut microbiota, but the mechanism of the antihypertensive effect of probiotics is insufficiently understood. Herein, we investigated the antihypertensive effect of Bifidobacterium lactis M8 and Lactobacillus rhamnosus M9 based on the integrative analysis of gut metagenome and fecal metabolome in high-fructose-treated mice.After 16 weeks intervention, Bifidobacterium lactis M8 and Lactobacillus rhamnosus M9 significantly reduced the median blood pressure by 16.92% aMetagenomic analysis revealed that the increased Lawsonia and Pyrolobus, and reduced Alistipes and Alloprevotella levels were tightly correlated with lowered blood pressure. Functionally, the decreased pathways of Base excision repair and D-Glutamine and D-glutamate metabolism were associated with blood pressure reduction. nd 15.39% in SBP, and 18.56% and 20.62% in DBP, respectively. Metabolomics data analysis further revealed that the probiotic interventions regulated lipid and vitamin metabolism in blood pressure control. Additionally, association analyses indicated a strong negative correlation between Alistipes and Steroid hormone biosynthesis, suggesting that Alistipes could affect blood pressure by changing steroid hormone levels. In conclusion, our findings indicate that the probiotic efficacies in alleviating hypertension are linked to specific gut microbes and metabolic pathways, which provide a potential mechanistic understanding of probiotics modulated blood pressure, paving the way for future assessment of the therapeutic potential of probiotics in hypertension management. |
